

**HIGHLIGHTS OF PRESCRIBING INFORMATION**

These highlights do not include all the information needed to use LUCENTIS safely and effectively. See full prescribing information for LUCENTIS.

**LUCENTIS® (ranibizumab injection) for intravitreal injection**  
Initial U.S. Approval: 2006

**RECENT MAJOR CHANGES**

Indications and Usage, Diabetic Retinopathy (1.4)	04/2017
Dosage and Administration (2)	03/2018
Dosage Forms and Strengths (3)	03/2018

**INDICATIONS AND USAGE**

LUCENTIS, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with:

- Neovascular (Wet) Age-Related Macular Degeneration (AMD) (1.1)
- Macular Edema Following Retinal Vein Occlusion (RVO) (1.2)
- Diabetic Macular Edema (DME) (1.3)
- Diabetic Retinopathy (DR) (1.4)
- Myopic Choroidal Neovascularization (mCNV) (1.5)

**DOSAGE AND ADMINISTRATION**

For ophthalmic intravitreal injection only (2.1)

- **Neovascular (Wet) Age-Related Macular Degeneration (AMD) (2.2):** LUCENTIS 0.5 mg (0.05 mL) is recommended to be administered by intravitreal injection once a month (approximately 28 days).
  - Although not as effective, patients may be treated with 3 monthly doses followed by less frequent dosing with regular assessment.
  - Although not as effective, patients may also be treated with one dose every 3 months after 4 monthly doses. Patients should be assessed regularly.
- **Macular Edema Following Retinal Vein Occlusion (RVO) (2.3):** LUCENTIS 0.5 mg (0.05 mL) is recommended to be administered by intravitreal injection once a month (approximately 28 days).
- **Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR) (2.4):** LUCENTIS 0.3 mg (0.05 mL) is recommended to be administered by intravitreal injection once a month (approximately 28 days).

- **Myopic Choroidal Neovascularization (mCNV) (2.5):** LUCENTIS 0.5 mg (0.05 mL) is recommended to be initially administered by intravitreal injection once a month (approximately 28 days) for up to three months. Patients may be retreated if needed.

**DOSAGE FORMS AND STRENGTHS**

- Single-use prefilled syringe designed to provide 0.05 mL for intravitreal injections:
  - 10 mg/mL solution (LUCENTIS 0.5 mg) (3)
  - 6 mg/mL solution (LUCENTIS 0.3 mg) (3)
- Single-use glass vial designed to provide 0.05 mL for intravitreal injections:
  - 10 mg/mL solution (LUCENTIS 0.5 mg) (3)
  - 6 mg/mL solution (LUCENTIS 0.3 mg) (3)

**CONTRAINDICATIONS**

- Ocular or periocular infections (4.1)
- Hypersensitivity (4.2)

**WARNINGS AND PRECAUTIONS**

- Endophthalmitis and retinal detachments may occur following intravitreal injections. Patients should be monitored following the injection (5.1).
- Increases in intraocular pressure (IOP) have been noted both pre- and post-intravitreal injection (5.2).
- There is a potential risk of arterial thromboembolic events following intravitreal use of VEGF inhibitors (5.3).
- Fatal events occurred more frequently in patients with DME and DR at baseline, who were treated monthly with LUCENTIS compared with control (5.4).

**ADVERSE REACTIONS**

- The most common adverse reactions (reported more frequently in LUCENTIS-treated subjects than control subjects) are conjunctival hemorrhage, eye pain, vitreous floaters, and increased IOP (6.2).

To report SUSPECTED ADVERSE REACTIONS, contact Genentech at 1-888-835-2555 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 03/2018

**FULL PRESCRIBING INFORMATION: CONTENTS\*****1 INDICATIONS AND USAGE**

- 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD)
- 1.2 Macular Edema Following Retinal Vein Occlusion (RVO)
- 1.3 Diabetic Macular Edema (DME)
- 1.4 Diabetic Retinopathy (DR)
- 1.5 Myopic Choroidal Neovascularization (mCNV)

**2 DOSAGE AND ADMINISTRATION**

- 2.1 General Dosing Information
- 2.2 Neovascular (Wet) Age-Related Macular Degeneration (AMD)
- 2.3 Macular Edema Following Retinal Vein Occlusion (RVO)
- 2.4 Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)
- 2.5 Myopic Choroidal Neovascularization (mCNV)
- 2.6 Preparation for Administration
- 2.7 Administration

**3 DOSAGE FORMS AND STRENGTHS****4 CONTRAINDICATIONS**

- 4.1 Ocular or Periocular Infections
- 4.2 Hypersensitivity

**5 WARNINGS AND PRECAUTIONS**

- 5.1 Endophthalmitis and Retinal Detachments
- 5.2 Increases in Intraocular Pressure
- 5.3 Thromboembolic Events
- 5.4 Fatal Events in Patients with DME and DR at Baseline

**6 ADVERSE REACTIONS**

- 6.1 Injection Procedure

- 6.2 Clinical Studies Experience
- 6.3 Immunogenicity
- 6.4 Postmarketing Experience

**7 DRUG INTERACTIONS****8 USE IN SPECIFIC POPULATIONS**

- 8.1 Pregnancy
- 8.2 Lactation
- 8.3 Females and Males of Reproductive Potential
- 8.4 Pediatric Use
- 8.5 Geriatric Use

**10 OVERDOSAGE****11 DESCRIPTION****12 CLINICAL PHARMACOLOGY**

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

**13 NONCLINICAL TOXICOLOGY**

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

**14 CLINICAL STUDIES**

- 14.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD)
- 14.2 Macular Edema Following Retinal Vein Occlusion (RVO)
- 14.3 Diabetic Macular Edema (DME)
- 14.4 Diabetic Retinopathy (DR)
- 14.5 Myopic Choroidal Neovascularization (mCNV)

**16 HOW SUPPLIED/STORAGE AND HANDLING****17 PATIENT COUNSELING INFORMATION**

\* Sections or subsections omitted from the Full Prescribing Information are not listed.

## FULL PRESCRIBING INFORMATION

### 1 INDICATIONS AND USAGE

LUCENTIS is indicated for the treatment of patients with:

#### 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD)

#### 1.2 Macular Edema Following Retinal Vein Occlusion (RVO)

#### 1.3 Diabetic Macular Edema (DME)

#### 1.4 Diabetic Retinopathy (DR)

#### 1.5 Myopic Choroidal Neovascularization (mCNV)

### 2 DOSAGE AND ADMINISTRATION

#### 2.1 General Dosing Information

FOR OPHTHALMIC INTRAVITREAL INJECTION.

*Vials:* A 5-micron sterile filter needle (19-gauge x 1-1/2 inch), a 1-mL Luer lock syringe and a 30-gauge x 1/2 inch sterile injection needle are needed but not included.

#### 2.2 Neovascular (Wet) Age-Related Macular Degeneration (AMD)

LUCENTIS 0.5 mg (0.05 mL of 10 mg/mL solution) is recommended to be administered by intravitreal injection once a month (approximately 28 days).

Although not as effective, patients may be treated with 3 monthly doses followed by less frequent dosing with regular assessment. In the 9 months after three initial monthly doses, less frequent dosing with 4-5 doses on average is expected to maintain visual acuity while monthly dosing may be expected to result in an additional average 1-2 letter gain. Patients should be assessed regularly [*see Clinical Studies (14.1)*].

Although not as effective, patients may also be treated with one dose every 3 months after 4 monthly doses. Compared with continued monthly dosing, dosing every 3 months over the next 9 months will lead to an approximate 5-letter (1-line) loss of visual acuity benefit, on average. Patients should be assessed regularly [*see Clinical Studies (14.1)*].

#### 2.3 Macular Edema Following Retinal Vein Occlusion (RVO)

LUCENTIS 0.5 mg (0.05 mL of 10 mg/mL solution) is recommended to be administered by intravitreal injection once a month (approximately 28 days).

In Studies RVO-1 and RVO-2, patients received monthly injections of LUCENTIS for 6 months. In spite of being guided by optical coherence tomography and visual acuity re-treatment criteria, patients who were then not treated at Month 6 experienced on average, a loss of visual acuity at Month 7, whereas patients who were treated at Month 6 did not. Patients should be treated monthly [*see Clinical Studies (14.2)*].

#### 2.4 Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)

LUCENTIS 0.3 mg (0.05 mL of 6 mg/mL solution) is recommended to be administered by intravitreal injection once a month (approximately 28 days).

#### 2.5 Myopic Choroidal Neovascularization (mCNV)

LUCENTIS 0.5 mg (0.05 mL of 10 mg/mL LUCENTIS solution) is recommended to be initially administered by intravitreal injection once a month (approximately 28 days) for up to 3 months. Patients may be retreated if needed [*(see Clinical Studies 14.5)*].

## 2.6 Preparation for Administration

### *Prefilled Syringe:*

The prefilled syringe is sterile and is for single use only. **Do not** use the product if the packaging is damaged or has been tampered with.

To prepare LUCENTIS for intravitreal administration, please adhere to these instructions for use. Read all the instructions carefully before using the prefilled syringe.

The opening of the sealed tray and all subsequent steps should be done under aseptic conditions.

For the intravitreal injection, a 30-gauge x ½ inch sterile injection needle should be used (not provided).

**Note: the dose must be set to 0.05 mL.**


---

### Device description


---

LUCENTIS prefilled syringes are available in 2 dose strengths:

- LUCENTIS 0.5 mg prefilled syringe with a CLEAR finger grip.



- LUCENTIS 0.3 mg prefilled syringe with an ORANGE finger grip.



Check the labels on the LUCENTIS carton, syringe tray and prefilled syringe to make sure you have the correct dose strength.




Figure 1

---

### Step 1: Prepare

---

- Make sure that your pack contains a sterile prefilled syringe in a sealed tray.
- Peel the lid off the syringe tray and, using aseptic technique, remove the syringe.

---

### Step 2: Inspect syringe

---

- LUCENTIS should be colorless to pale yellow.
- **Do not** use the prefilled syringe if:
  - the syringe cap is detached from the Luer lock.
  - the syringe is damaged.
  - particulates, cloudiness, or discoloration are visible.

---

### Step 3: Remove syringe cap

---

- Snap off (**do not** turn or twist) the syringe cap (see Figure 2).





Figure 2

---

### Step 4: Attach needle

---

- Attach a 30G x ½ inch sterile injection needle firmly onto



the syringe by screwing it tightly onto the Luer lock (see Figure 3).

- Carefully remove the needle cap by pulling it straight off.

**Note: Do not wipe the needle at any time.**

---

### Step 5: Dislodge air bubbles

---

- Hold the syringe with the needle pointing up.
- If there are any air bubbles, gently tap the syringe with your finger until the bubbles rise to the top (see Figure 4).




Figure 4

---

### Step 6: Expel air and adjust drug dose

---

- Hold the syringe at eye level, and carefully push the plunger rod until the **edge below the dome** of the rubber stopper is aligned with the 0.05 mL dose mark (see Figure 5).




Figure 5

**Note: The plunger rod is not attached to the rubber stopper – this is to prevent air being drawn into the syringe.**

---

### Step 7: Inject

---

- The injection procedure should be carried out under aseptic conditions.
- Insert the needle into the injection site.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.